- Sanofi terminated phase 1 trial and research program for SAR448272.
Sanofi terminated a phase 1 trial and the SAR448272 research program under the collaboration with Nurix. Shares fell 34% in after-hours trading. Nurix said it remains eligible for other milestone payments and royalties from the agreement.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.